Cipla

Invagen Pharmaceuticals, a wholly owned subsidiary of Cipla announced that it has entered into a strategic partnership with Qilu…

SBP Group subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) has granted Cipla exclusive rights to develop and commercialise…

The action follows inspections in June 2026 involving Reactin Plus Tablets, a Schedule H prescription medicine.

Cipla and its wholly owned subsidiary Cipla USA announced that it has received US Food and Drug Administration (FDA) approval for…

Author Vijay Martis explains how Cipla's business model, strategy and purpose shaped its growth over nine decades

Cipla Limited has announced that it will acquire a 100% stake in Inzpera Healthsciences for about ₹110.65 crore. Once completed,…

Cipla to distribute and promote Lilly’s tirzepatide as Yurpeak across India at the same price as Mounjaro, expanding access for…

As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging AI across nearly every aspect…

iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus, with a core…

Through the agreement, the existing licensees, Aurobindo, Cipla and Viatris, will be able to develop,  manufacture and supply…